#Public health

AMR finds 75 % of hetastarch recipients underwent surgical procedures Arlington Medical Assets.

‘The brand new Plasma Expander Medical center Inpatient Profile Study is a good complementary study to our Plasma Expander Medical center Purchasing Audit,’ mentioned Mary Walker, R.Ph., MBA, therapeutics principal director at AMR. ‘As the Purchasing Audit enables pharmaceutical businesses to monitor the market size, market marketplace or potential influences of plasma expanders, the Inpatient Profile Study allows these same companies to monitor plasma expander users and prescribers.’.. AMR finds 75 % of hetastarch recipients underwent surgical procedures Arlington Medical Assets , a company of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that for the January – May 2009 time frame, a significantly higher %age of hetastarch recipients underwent a medical procedure in comparison with those receiving albumin/plasma protein fraction .The ADDF and AFTD are particularly interested in defining and validating clinical outcomes for FTD subpopulations for use in medical trials; FTD-relevant imaging brokers; CSF – and plasma-structured assays; and TDP-43 and tau-focused biomarkers specifically highly relevant to FTD populations The ADDF/AFTD Biomarker Program will provide funding for $150,000 each with the chance of follow-on funding. Applications may be submitted by non-profit academic establishments and for-profit biotechnology companies, both private and public, worldwide. Please be aware that funding to biotechnology companies is typically produced as a program-related investment..